IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Aims to Fast-Track Release of Hyalolex in Recreational Cannabis States

As a first mover in the cannabis-based combination therapy space, India Globalization Capital (NYSE AMERICAN: IGC) is preparing for the launch of its breakthrough treatment aimed at reducing beta-amyloid building up in Alzheimer’s patients, Hyalolex. The classification as a combination therapy enables the company to bring the product to market significantly faster than most pharmaceuticals, because Hyalolex does not need FDA approval. An article discussing this reads: “This hugely accelerated introduction of Hyalolex can only be accomplished in states where medical cannabis is legal and where the ailment (in this case Alzheimer’s) is an approved medical condition. In states where recreational cannabis has been approved, IGC doesn’t have to contend with whether or not Alzheimer’s is an approved medical condition in order to bring its treatment to market. Therefore, these states (recreational marijuana states like California, Colorado, Oregon, etc.) will be targeted first with IGC’s cannabis-based Alzheimer’s treatment.”

To view the full article, visit http://nnw.fm/20tZ3

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us.